Cardiology journalPub Date : 2025-01-01Epub Date: 2025-05-22DOI: 10.5603/cj.104310
José-Manuel Rubio-Campal, Carlos Rodriguez Lopez, Carla Lázaro Rivera, Francisco de Asís Díaz Cortegana, Loreto Bravo Calero, Cristina Aguilera Agudo, José María Romero-Otero, José Tuñón Fernández
{"title":"Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan.","authors":"José-Manuel Rubio-Campal, Carlos Rodriguez Lopez, Carla Lázaro Rivera, Francisco de Asís Díaz Cortegana, Loreto Bravo Calero, Cristina Aguilera Agudo, José María Romero-Otero, José Tuñón Fernández","doi":"10.5603/cj.104310","DOIUrl":"10.5603/cj.104310","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril/valsartan (S/V) improve left ventricular ejection fraction (LVEF) in heart failure patients, but the magnitude of improvement may depend on baseline values.</p><p><strong>Methods: </strong>We analyzed whether baseline LVEF can predict its improvement in patients with LVEF ≤ 45% receiving S/V. Patients were divided into 4 groups (G) according to baseline LVEF (G1: ≤ 20%; G2: 21-30%; G3: 31-40%; G4: 41-45%).</p><p><strong>Results: </strong>We included 256 patients (age 73 ± 12 years; 73% male; 174 ischemic cardiomyopathy [CM], 82 nonischemic CM) and assessed LVEF at S/V initiation and at 6 and 12 months of therapy. Baseline LVEF (%) values (overall 30.9 ± 8.6) were: G1: 17.3 ± 3.3; G2: 27.5 ± 2.4; G3: 35.5 ± 2; G4: 44.4 ± 1. LVEF increased in 62% of patients, reaching 34.3 ± 10.4% and 35.5 ± 11.2% at 6 and 12 months, respectively (p < 0.001). A significantly higher absolute LVEF increase was found in Groups 3 (7.2 ± 4.3) and 4 (4.2 ± 3.05) than in Groups 1 (0.6 ± 1.5) and 2 (3.5 ± 1.5), in women (5.9 ± 4.4 vs. 4.1 ± 4.5; p < 0.001), with high S/V doses (7.4 ± 4.7 vs. 4.3 ± 4.4; p < 0.001), and in nonischemic CM (6.3 ± 4.9 vs. 3.8 ± 4.2; p < 0.001). On multivariate analysis, female sex (OR 2.18; 95% CI [1.06-4.48]; p = 0.034), high dose (OR 3.38; 95% CI [1.10-10.34]; p = 0.033), and baseline LVEF > 30% (OR 8.62; 95% CI [4.69-15.82]; p = 0.001) were significant predictors of LVEF improvement.</p><p><strong>Conclusions: </strong>LVEF improvement with S/V depends on baseline values, sex, and dose.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"270-277"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michał Pałuchowski, Olga Jakubik, Piotr Tyślerowicz, Arkadiusz Pietrasik, Aleksandra Gąsecka
{"title":"Paradoxical embolism via patent foramen ovale: a rare cause of myocardial infarction in an air traveler.","authors":"Michał Pałuchowski, Olga Jakubik, Piotr Tyślerowicz, Arkadiusz Pietrasik, Aleksandra Gąsecka","doi":"10.5603/cj.99831","DOIUrl":"10.5603/cj.99831","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 3","pages":"332-333"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2025-02-25DOI: 10.5603/cj.99070
Daniel Gondko, Patrycja Dębiec, Jakub Roman, Nikodem Pietrzak, Krzysztof Kocot, Jacek Kusa
{"title":"Galectin-3: Heart failure biomarker in pediatric heart defects.","authors":"Daniel Gondko, Patrycja Dębiec, Jakub Roman, Nikodem Pietrzak, Krzysztof Kocot, Jacek Kusa","doi":"10.5603/cj.99070","DOIUrl":"10.5603/cj.99070","url":null,"abstract":"<p><p>Galectin-3 (Gal-3), a β-galactoside-binding lectin, has emerged as a potential diagnostic and prognostic biomarker for various diseases, including certain heart and kidney diseases, as well as cancer. Its significance is particularly notable in the context of congenital heart defects (CHD), which are the most prevalent congenital malformations, occurring in 6 to 8 out of every 1000 live births. Symptoms of heart failure (HF) in patients with congenital heart defects can manifest early in life, but in some cases, the disease progresses gradually, leading to a gradual decline in quality of life and the development of various complications. This variability underscores the need for early biomarkers to detect HF development in pediatric patients. Gal-3 plays a key role in myocardial remodeling, making it a promising candidate for advancing the diagnosis and management of HF in CHD patients. It is especially relevant in pediatric care, where early detection and intervention can significantly alter disease progression and patient outcomes. This review aims to consolidate current knowledge on the utility of Gal-3 in predicting HF among pediatric patients with CHD, highlighting its potential in changing the direction of diagnosis and treatment in this vulnerable patient population.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"175-188"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2025-05-13DOI: 10.5603/cj.105140
Krzysztof J Filipiak, Matteo Cameli, Santiago J Freire, Rahima Gabulova, Gulnoz Khamidullaeva, Anna Tomaszuk-Kazberuk, Agnieszka Kuzior, Francisco Javier Martinez-Martin, Ulvi Mirzoyev, Ulugbek Nizamov, Nguyen Van Tan, Aleksandra Gąsecka
{"title":"EASY OR NOT. European-Asian Six countries Yearly consensus On Recent guidelines: arterial hypertension, atrial fibrillation, chronic coronary syndromes, and peripheral artery diseases. Novel Or conventional Treatment options for these patients. Position Paper 2024.","authors":"Krzysztof J Filipiak, Matteo Cameli, Santiago J Freire, Rahima Gabulova, Gulnoz Khamidullaeva, Anna Tomaszuk-Kazberuk, Agnieszka Kuzior, Francisco Javier Martinez-Martin, Ulvi Mirzoyev, Ulugbek Nizamov, Nguyen Van Tan, Aleksandra Gąsecka","doi":"10.5603/cj.105140","DOIUrl":"10.5603/cj.105140","url":null,"abstract":"<p><p>The 2024 guidelines of the European Society of Cardiology (ESC) refer to four very important therapeutic areas: arterial hypertension, atrial fibrillation, chronic coronary syndromes and peripheral artery disease. The ESC countries and their institutional members share a common goal of reducing the burden of cardiovascular diseases, which remain the leading cause of death worldwide. Experts from these six countries - three from Europe and three from Asia - gathered at the annual meeting to briefly present the epidemiological situation regarding selected issues addressed in the 2024 ESC guidelines, and to create a document highlighting the significant progress in pharmacotherapy. The new guidelines allow us to identify particularly important therapeutic areas and unmet pharmaceutical needs within the four treatment guidelines developed by the ESC in 2024. While discussing each of these four documents, 10 subjectively selected points were chosen to highlight what should be kept in mind in daily clinical practice. Altogether, a range of all-risk categories are represented, and the observations made in this position paper are of a universal nature.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"213-227"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2025-03-31DOI: 10.5603/cj.103680
Marcin Wełnicki, Iwona Gorczyca-Głowacka, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski, Jarosław D Kasprzak, Przemysław Leszek, Anna Tomaszuk-Kazberuk, Maria Łukasiewicz, Mariusz Tomaniak, Stanisław Surma, Agnieszka Mickiewicz, Krzysztof Narkiewicz, Miłosz Jaguszewski, Zbigniew Krasiński, Daniel Śliż, Artur Mamcarz, Filip M Szymański, Marcin Barylski, Beata Wożakowska-Kapłon, Krzysztof J Filipiak
{"title":"Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot.","authors":"Marcin Wełnicki, Iwona Gorczyca-Głowacka, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski, Jarosław D Kasprzak, Przemysław Leszek, Anna Tomaszuk-Kazberuk, Maria Łukasiewicz, Mariusz Tomaniak, Stanisław Surma, Agnieszka Mickiewicz, Krzysztof Narkiewicz, Miłosz Jaguszewski, Zbigniew Krasiński, Daniel Śliż, Artur Mamcarz, Filip M Szymański, Marcin Barylski, Beata Wożakowska-Kapłon, Krzysztof J Filipiak","doi":"10.5603/cj.103680","DOIUrl":"10.5603/cj.103680","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"107-119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2025-03-10DOI: 10.5603/cj.99019
Roberto Gómez-Sánchez, Carlos Ortiz-Bautista, Javier Castrodeza, Zorba Blázquez-Bermejo, Eduardo Zataraín-Nicolás, Adolfo Villa, Ricardo Sanz-Ruiz, Jaime Elízaga, Javier Bermejo
{"title":"The role of endomyocardial biopsy for surveillance of cardiac allograft rejection: time to move on?","authors":"Roberto Gómez-Sánchez, Carlos Ortiz-Bautista, Javier Castrodeza, Zorba Blázquez-Bermejo, Eduardo Zataraín-Nicolás, Adolfo Villa, Ricardo Sanz-Ruiz, Jaime Elízaga, Javier Bermejo","doi":"10.5603/cj.99019","DOIUrl":"10.5603/cj.99019","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"203-205"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2024-12-03DOI: 10.5603/cj.98481
Niya Mileva, Teodora Yaneva-Sirakova, Irina Hristova, Despina Georgieva, Greta Koleva, Dimitra Psalla, Ranko Georgiev, Dobrin Vassilev
{"title":"Rationale and design of the MICE study: Exploration of the temporal relation between electrical and mechanical events during myocardial ischemia.","authors":"Niya Mileva, Teodora Yaneva-Sirakova, Irina Hristova, Despina Georgieva, Greta Koleva, Dimitra Psalla, Ranko Georgiev, Dobrin Vassilev","doi":"10.5603/cj.98481","DOIUrl":"10.5603/cj.98481","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"90-97"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohsen Mohandes, Cristina Moreno, Luis Mauricio Torres, Humberto Coimbra, José Luis Ferreiro
{"title":"IVUS-guided cap puncture of a stumpless chronic total occlusion with sliptream technique.","authors":"Mohsen Mohandes, Cristina Moreno, Luis Mauricio Torres, Humberto Coimbra, José Luis Ferreiro","doi":"10.5603/cj.99193","DOIUrl":"10.5603/cj.99193","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 1","pages":"104-105"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karolina Jasińska-Gniadzik, Michał Łomiak, Jerzy Pręgowski, Zbigniew Chmielak, Piotr Kasprzyk, Jan Kasprzyk, Rafał Gałąska, Michał Chmielecki, Miłosz J Jaguszewski, Marcin Fijałkowski, Aleksandra Topolska, Michał Sekuła, Marcin Grabowski, Janusz Kochman, Adam Rdzanek, Piotr Scislo, Agnieszka Kapłon-Cieślicka, Renata Główczyńska, Monika Budnik, Radosław Piątkowski, Łukasz Kołtowski, Arkadiusz Pietrasik, Aleksandra Gąsecka
{"title":"Validation of the COAPT risk score in Polish patients undergoing transcatheter edge-to-edge repair of severe, functional mitral regurgitation: a multicenter, observational study.","authors":"Karolina Jasińska-Gniadzik, Michał Łomiak, Jerzy Pręgowski, Zbigniew Chmielak, Piotr Kasprzyk, Jan Kasprzyk, Rafał Gałąska, Michał Chmielecki, Miłosz J Jaguszewski, Marcin Fijałkowski, Aleksandra Topolska, Michał Sekuła, Marcin Grabowski, Janusz Kochman, Adam Rdzanek, Piotr Scislo, Agnieszka Kapłon-Cieślicka, Renata Główczyńska, Monika Budnik, Radosław Piątkowski, Łukasz Kołtowski, Arkadiusz Pietrasik, Aleksandra Gąsecka","doi":"10.5603/cj.100877","DOIUrl":"10.5603/cj.100877","url":null,"abstract":"<p><strong>Background: </strong>The COAPT risk score, developed based on the COAPT trial, is a tool to predict the risk of death or hospitalization for heart failure (HFH) within two years after transcatheter edge-to-edge repair (TEER) of mitral regurgitation using a MitraClip device. We aimed to validate the Score in a Polish population.</p><p><strong>Methods: </strong>Patients with severe mitral regurgitation who underwent TEER with MitraClip at three cardiology centers in Poland between November 2015 and February 2023 were included. Patients were divided into two groups based on the COAPT trail criteria: COAPT eligible and COAPT non-eligible. Clinical data were collected from medical records and the COAPT risk score was calculated for each patient. Outcomes were collected during the two-year follow-up period. The primary endpoint was a composite of all-cause mortality and HFH at two-year follow-up and evaluated in the overall cohort and separately for COAPT-eligible and -non-eligible patients.</p><p><strong>Results: </strong>A total of 225 patients were included in the study: 134 COAPT eligible (60%) and 91 COAPT non-eligible (40%). Higher COAPT risk score was associated with increased risk of primary endpoint in the overall population and in COAPT-eligible patients. The score demonstrated moderate discrimination (area under curve [AUC] = 0.581) and poor calibration (Hosmer-Lemeshow [HL] p = 0.085) in the overall population, whereas it showed moderate discrimination (AUC = 0.600) and good calibration (HL p = 0.308) in COAPT-eligible patients.</p><p><strong>Conclusions: </strong>In Polish patients fulfilling COAPT criteria, the COAPT risk score has moderate predictive value for post-procedural outcomes. In COAPT non-eligible patients, novel tools are required to predict outcomes.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 3","pages":"258-269"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}